Literature DB >> 8099886

Analysis of uroporphyrinogen decarboxylase complementary DNAs in sporadic porphyria cutanea tarda.

J R Garey1, K F Franklin, D A Brown, L M Harrison, K M Metcalf, J P Kushner.   

Abstract

BACKGROUND: Sporadic porphyria cutanea tarda (S-PCT) has been considered an acquired disease because of the generation of liver-specific inhibitors of uroporphyrinogen decarboxylase (URO-D) activity. Several families have been described with S-PCT in multiple generations, raising the possibility of an inherited basis for the disease. To determine if S-PCT is associated with mutant URO-Ds that might be sensitive to liver-specific inhibitors, a molecular analysis of genomic and hepatocellular URO-Ds was undertaken.
METHODS: Total RNA from lymphoid cell lines from three unrelated patients with S-PCT and poly A+ RNA from liver biopsy samples from two additional patients was used as a template for single-stranded cDNA synthesis, and URO-D sequences were amplified and sequenced. DNA prepared from peripheral blood leukocytes was used as a template to polymerase chain reaction (PCR) amplify the promoter region of the URO-D gene. Sequencing of PCR products was performed completely in both directions by the chain termination method using a variety of custom oligonucleotide primers.
RESULTS: Ten URO-D alleles were sequenced, and no mutations were found. The promoter region of the URO-D gene was also normal.
CONCLUSIONS: It is concluded that S-PCT is not due to mutations at the URO-D locus. If inherited factors are involved, other loci must be affected.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8099886     DOI: 10.1016/0016-5085(93)90022-5

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  10 in total

1.  Crystal structure of human uroporphyrinogen decarboxylase.

Authors:  F G Whitby; J D Phillips; J P Kushner; C P Hill
Journal:  EMBO J       Date:  1998-05-01       Impact factor: 11.598

Review 2.  [Hepatic porphyrias and alcohol].

Authors:  M O Doss; A Kühnel; U Gross; I Sieg
Journal:  Med Klin (Munich)       Date:  1999-06-15

Review 3.  Erythropoietic and hepatic porphyrias.

Authors:  U Gross; G F Hoffmann; M O Doss
Journal:  J Inherit Metab Dis       Date:  2000-11       Impact factor: 4.982

4.  Porphyria cutanea tarda: multiplicity of risk factors including HFE mutations, hepatitis C, and inherited uroporphyrinogen decarboxylase deficiency.

Authors:  Norman G Egger; Douglas E Goeger; Deborah A Payne; Emil P Miskovsky; Steven A Weinman; Karl E Anderson
Journal:  Dig Dis Sci       Date:  2002-02       Impact factor: 3.199

5.  Mouse uroporphyrinogen decarboxylase: cDNA cloning, expression, and mapping.

Authors:  C Wu; W Xu; C A Kozak; R J Desnick
Journal:  Mamm Genome       Date:  1996-05       Impact factor: 2.957

Review 6.  Uroporphyrinogen decarboxylase.

Authors:  G H Elder; A G Roberts
Journal:  J Bioenerg Biomembr       Date:  1995-04       Impact factor: 2.945

7.  Familial porphyria cutanea tarda: characterization of seven novel uroporphyrinogen decarboxylase mutations and frequency of common hemochromatosis alleles.

Authors:  M Mendez; L Sorkin; M V Rossetti; K H Astrin; A M del C Batlle; V E Parera; G Aizencang; R J Desnick
Journal:  Am J Hum Genet       Date:  1998-11       Impact factor: 11.025

8.  Uroporphyrinogen decarboxylase: complete human gene sequence and molecular study of three families with hepatoerythropoietic porphyria.

Authors:  M J Moran-Jimenez; C Ged; M Romana; R Enriquez De Salamanca; A Taïeb; G Topi; L D'Alessandro; H de Verneuil
Journal:  Am J Hum Genet       Date:  1996-04       Impact factor: 11.025

9.  Isolation and characterization of extragenic mutations affecting the expression of the uroporphyrinogen decarboxylase gene (HEM12) in Sacharomyces cerevisiae.

Authors:  T Zoładek; A Chełstowska; R Labbe-Bois; J Rytka
Journal:  Mol Gen Genet       Date:  1995-05-20

10.  A mouse model of familial porphyria cutanea tarda.

Authors:  J D Phillips; L K Jackson; M Bunting; M R Franklin; K R Thomas; J E Levy; N C Andrews; J P Kushner
Journal:  Proc Natl Acad Sci U S A       Date:  2001-01-02       Impact factor: 11.205

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.